Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-Current Debt (2016 - 2024)

Capricor Therapeutics (CAPR) has 12 years of Non-Current Debt data on record, last reported at $3.4 million in Q3 2024.

  • For Q3 2024, Non-Current Debt changed 0.0% year-over-year to $3.4 million; the TTM value through Sep 2024 reached $3.4 million, changed 0.0%, while the annual FY2023 figure was $3.4 million, 0.0% changed from the prior year.
  • Non-Current Debt reached $3.4 million in Q3 2024 per CAPR's latest filing, roughly flat from $3.4 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $3.4 million in Q1 2020 and bottomed at $71471.0 in Q4 2020.
  • Average Non-Current Debt over 5 years is $3.0 million, with a median of $3.4 million recorded in 2020.
  • Peak YoY movement for Non-Current Debt: plummeted 97.88% in 2020, then soared 4623.96% in 2021.
  • A 5-year view of Non-Current Debt shows it stood at $71471.0 in 2020, then skyrocketed by 4623.96% to $3.4 million in 2021, then changed by 0.0% to $3.4 million in 2022, then changed by 0.0% to $3.4 million in 2023, then changed by 0.0% to $3.4 million in 2024.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $3.4 million in Q3 2024, $3.4 million in Q2 2024, and $3.4 million in Q1 2024.